1. Scrip
  2. >>Business
  3. >>Deals

AstraZeneca Signs AI Deal To Pursue Novel Parkinson's Drugs

 
• By Lucie Ellis-Taitt

AstraZeneca is the most recent big pharma to team up with an artificial intelligence business – following in the footsteps of Takeda, Johnson & Johnson, Sanofi and GlaxoSmithKline – having signed a drug discovery deal with Boston-based BERG.

MT1704_AI_1200x675
AstraZeneca To Boost Early-Stage CNS Pipeline Via AI Drug Discovery Deal

AstraZeneca PLC is teaming up with artificial intelligence biopharma business BERG to identify and evaluate novel targets and therapeutics to treat neurological disorders such as Parkinson’s disease – making it the latest of a string of big pharmas to sign discovery and development deals with AI technology firms.

Under this research arrangement, AstraZeneca will initially provide BERG with its curated library of central

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Roche Reveals Another US Manufacturing Site As Tariff Pressures Seem To Ease

 
• By Mandy Jackson

Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.

Trump’s MFN Executive Order More Rhetoric Than Action

 
• By Jessica Merrill

The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.